For research use only. Not for therapeutic Use.
Ceftobiprole (Cat No.:I005926) is a broad-spectrum cephalosporin antibiotic used for the treatment of bacterial infections. It belongs to the fifth generation of cephalosporins and exhibits activity against a wide range of Gram-positive and Gram-negative bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and penicillin-resistant Streptococcus pneumoniae. Ceftobiprole works by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs). This mechanism of action disrupts the integrity of the bacterial cell wall, leading to cell death. Ceftobiprole has been approved for the treatment of complicated skin and skin structure infections (cSSSI) and community-acquired pneumonia (CAP).
| Catalog Number | I005926 |
| CAS Number | 209467-52-7 |
| Synonyms | Ceftobiprole; BAL 9141; AC1OCFF8; Zeftera; UNII-5T97333YZK; BAL-9141; BAL9141.;(6R,7R)-7-((Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(hydroxyimino)acetamido)-8-oxo-3-((E)-((R)-2-oxo-[1,3/’-bipyrrolidin]-3-ylidene)methyl)-5-thia-1-azabicyclo[4.2.0]oct-2- |
| Molecular Formula | C20H22N8O6S2 |
| Purity | ≥95% |
| Solubility | Soluble in DMSO, not in water |
| Storage | 0 - 4°C for short term ,or -20 °C for long term |
| Overview of Clinical Research | Originator: Basilea Pharmaceutica; Roche<br /> |
| IUPAC Name | (6R,7R)-7-[[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-hydroxyiminoacetyl]amino]-8-oxo-3-[(E)-[2-oxo-1-[(3R)-pyrrolidin-3-yl]pyrrolidin-3-ylidene]methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
| InChI | InChI=1S/C20H22N8O6S2/c21-20-24-14(26-36-20)11(25-34)15(29)23-12-17(31)28-13(19(32)33)9(7-35-18(12)28)5-8-2-4-27(16(8)30)10-1-3-22-6-10/h5,10,12,18,22,34H,1-4,6-7H2,(H,23,29)(H,32,33)(H2,21,24,26)/b8-5+,25-11-/t10-,12-,18-/m1/s1 |
| InChIKey | VOAZJEPQLGBXGO-SDAWRPRTSA-N |
| SMILES | C1CNCC1N2CCC(=CC3=C(N4C(C(C4=O)NC(=O)C(=NO)C5=NSC(=N5)N)SC3)C(=O)O)C2=O |
| Reference | <br /> |
